| Title: |
Genetic Evidence for Repurposing of GLP1R (Glucagon‐Like Peptide‐1 Receptor) Agonists to Prevent Heart Failure |
| Authors: |
Iyas Daghlas, Ville Karhunen, Devleena Ray, Verena Zuber, Stephen Burgess, Philip S. Tsao, Julie A. Lynch, Kyung Min Lee, Benjamin F. Voight, Kyong‐Mi Chang, Emma H. Baker, Scott M. Damrauer, Joanna M. M. Howson, Marijana Vujkovic, Dipender Gill |
| Source: |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 13 (2021) |
| Publisher Information: |
Wiley, 2021. |
| Publication Year: |
2021 |
| Collection: |
LCC:Diseases of the circulatory (Cardiovascular) system |
| Subject Terms: |
diabetes mellitus, ejection fraction, GLP1R, heart failure, Mendelian randomization, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| More Details: |
Background This study was designed to investigate the genetic evidence for repurposing of GLP1R (glucagon‐like peptide‐1 receptor) agonists to prevent heart failure (HF) and whether the potential benefit exceeds the benefit conferred by more general glycemic control. Methods and Results We applied 2‐sample Mendelian randomization of genetically proxied GLP1R agonism on HF as the main outcome and left ventricular ejection fraction as the secondary outcome. The associations were compared with those of general glycemic control on the same outcomes. Genetic associations were obtained from genome‐wide association study summary statistics of type 2 diabetes mellitus (228 499 cases and 1 178 783 controls), glycated hemoglobin (n=344 182), HF (47,309 cases and 930 014 controls), and left ventricular ejection fraction (n=16 923). Genetic proxies for GLP1R agonism associated with reduced risk of HF (odds ratio per 1 mmol/mol decrease in glycated hemoglobin 0.75; 95% CI, 0.64–0.87; P=1.69×10−4), and higher left ventricular ejection fraction (SD change in left ventricular ejection fraction per 1 mmol/mol decrease in glycated hemoglobin 0.22%; 95% CI, 0.03–0.42; P=0.03). The magnitude of these benefits exceeded those expected from improved glycemic control more generally. The results were similar in sensitivity analyses, and we did not find evidence to suggest that these associations were mediated by reduced coronary artery disease risk. Conclusions This genetic evidence supports the repurposing of GLP1R agonists for preventing HF. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2047-9980 |
| Relation: |
https://doaj.org/toc/2047-9980 |
| DOI: |
10.1161/JAHA.120.020331 |
| Access URL: |
https://doaj.org/article/765c724d18cb4ab69836628c5edb9da0 |
| Accession Number: |
edsdoj.765c724d18cb4ab69836628c5edb9da0 |
| Database: |
Directory of Open Access Journals |
